Compare RCMT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | CGEN |
|---|---|---|
| Founded | 1971 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.0M | 191.1M |
| IPO Year | 1997 | 2001 |
| Metric | RCMT | CGEN |
|---|---|---|
| Price | $27.77 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $36.00 | $5.00 |
| AVG Volume (30 Days) | 74.5K | ★ 411.7K |
| Earning Date | 04-03-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.38 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $11.89 | N/A |
| Revenue Next Year | $12.46 | $75.09 |
| P/E Ratio | $52.83 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $1.30 |
| 52 Week High | $32.50 | $3.24 |
| Indicator | RCMT | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 66.52 | 40.66 |
| Support Level | $17.77 | $1.98 |
| Resistance Level | $32.39 | $2.35 |
| Average True Range (ATR) | 1.18 | 0.09 |
| MACD | 0.47 | 0.02 |
| Stochastic Oscillator | 88.80 | 65.82 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.